top of page
The Professional Network for Healthcare Experts
South Korea approves Jascayd nerandomilast for idiopathic pulmonary fibrosis
South Korea has authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, providing a new national treatment option for patients with progressive lung scarring.
nuaxia
3 days ago2 min read
Saudi regulator approves Jascayd for idiopathic pulmonary fibrosis
Saudi Arabia has approved Jascayd for adults with idiopathic pulmonary fibrosis following Phase III evidence showing reduced decline in lung function.
nuaxia
Oct 52 min read
bottom of page